A Phase 2 interventional study of Exercise Intervention and Biospecimen Collection in Breast Carcinoma and Prostate Carcinoma, sponsored by OHSU Knight Cancer Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by OHSU Knight Cancer Institute · Phase 2, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Breast Neoplasms by OHSU Knight Cancer Institute — 3 open to participants now, 4 under way, none of them phase 3. Breast Neoplasms · OHSU Knight Cancer Institute.
Among the 29 studies in Breast Neoplasms by OHSU Knight Cancer Institute, this one is the 2nd largest by planned enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2024, is one of 5 in phase 2, and was the 29th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →3 of the 29 studies in Breast Neoplasms by OHSU Knight Cancer Institute are open now, in 1 country. Recruiting first, the newest first:
OHSU Knight Cancer Institute · Sites in United States
Ages 18–100
OHSU Knight Cancer Institute · Sites in United States
Ages 40–74 · Women only · Healthy volunteers
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 2
First in 2001; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 37 across the 24 interventional studies, 98 across the 5 observational. Of the 22 that completed or were terminated, 7 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
OHSU Knight Cancer Institute is the lead sponsor of 243 studies on the registry; 42 are open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 15 (56%) have results posted.
1 of the studies in Breast Neoplasms by OHSU Knight Cancer Institute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04993313OHSU Knight Cancer InstituteStandard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study | 2027-02-28 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Breast Neoplasms by OHSU Knight Cancer Institute, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This phase II trial tests how well an exercise intervention, Exercising Together, works in preventing declines in physical and mental health in couples during radiation treatment for cancer. Treatments for cancer can cause side effects such as fatigue as well as strain on relationships. Exercising Together is a partnered exercise program that adds communication, collaboration and support between partners during exercise to fortify the relationship and amplify the benefits of physical training. Exercising Together program may be effective on the mental and physical health of couples during radiation treatment for cancer.
PRIMARY OBJECTIVE:
I. To test the effectiveness and mechanisms of the adapted Exercise Together intervention on mental and physical health of couples (Aims 1 \& 2).
SECONDARY OBJECTIVE:
I. To gain better understanding of the implementation context and implementation outcomes (Aim 3).
ADMINISTRATIVE SUPPLEMENT AIMS:
I. To develop and apply novel computational models that analyze the joint effects of three or more temporally co-occurring modifiable risk factors on cancer outcomes.
II. Adequate access to temporal data at the individual level for each risk factor by using 24-hour actigraphy data collected on cancer dyads participating in the parent trial.
III. Applying a structural equation modeling approach to examine congruence of co-occurring movement behaviors within and between cancer dyads participating in behavioral intervention trial to improve dyadic cancer outcomes.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients and partners undergo Exercising Together exercise program during radiation therapy on study. Patients also undergo collection of blood samples throughout the trial.
ARM II: Patients and partners receive educational materials specific to exercise. Patients also undergo collection of blood samples throughout the trial.
The criteria were revised on the registry on Oct 13, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
INTERVENTION (SURVIVORS) INCLUSION
Scheduled to receive radiation therapy for curative intent
Confirmed by review of the EMR and subsequently recorded in Survivor Health History. In cases where the EMR isn't clear, their OHSU provider will be contacted for confirmation/ For non-OHSU patients, we'll initially collect their cancer health history by a self-report questionnaire and confirm when we receive the survivor's outside medical record (through a signed Release of Information)
Co-residing with an intimate partner or spouse who is willing to participate
18 years of age and older
\< 2 structured strength training sessions for less than 30 minutes per week in the last month
Home internet sufficient for videoconferencing
Signed
Willing to be randomized into either study arm and adhere to study protocol
Exclusion Criteria:
Cognitive difficulties that preclude answering the survey questions, participating in the exercise classes or performance tests, or providing
A medical condition, movement or neurological disorder, or medication use that contraindicates participation in moderate intensity exercise. Specific include the following: poorly controlled diabetes, recent cardiac event, neuromuscular disease, untreated orthostatic hypertension, recent surgery, acute hernia, acute rheumatoid arthritis, severe memory disorders, severe balance disorder, inability to ambulate without a walker or wheelchair, inability to stand for 3 minutes, severe hearing or vision problem
Confirmed by a combination of reviewing the EMR, self-report on the Health History Questionnaire, Charlson Comorbidity Index questionnaire, and/or by physician clearance. If in the professional opinion of the Principal Investigator, Dr. Kerri Winters-Stone, contraindications other than those identified by the patient or physician are present, she may consider the participant ineligible. For Spouse/Partner: must answer 'No'; to American College of Sports Medicine pre-participation screening questions. If spouse/partner answers 'Yes'; to either question they may be required to obtain physician clearance prior to becoming eligible. Physician clearance may also be requested at the discretion of the principal investigator.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients and partners undergo Exercising Together supervised group exercise program using live remote video conference technology over 75 minutes three times a week (TIW) for 8 weeks during radiation therapy on study. Patients also undergo collection of blood samples using self-collection methods throughout the trial.
Other: Exercise Intervention · Procedure: Biospecimen Collection
Patients and partners receive educational materials specific to exercise. Patients also undergo collection of blood samples using self collection methods throughout the trial.
Procedure: Biospecimen Collection · Other: Educational Intervention
Undergo Exercise Together exercise program, a supervised group exercise program delivered online, using a live remote format
Undergo collection of blood samples
Also known as: Biological Sample Collection, Biological Sample Collection, Biospecimen Collected, Biospecimen Collection, Specimen Collection
Receive educational materials
Also known as: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational
Physical functioning
Measured by the Physical Performance Battery (PPB) to determine a person's ability to perform daily tasks independently. The PPB consists of 3 timed tests: 5 repeated chair stands, standing balance, and usual pace gait speed over 4 meters. Each test is scored 0 (unable) to 4 (completes without difficulty), based on quartiles of performance, then scores are summed. The possible range of scores is 0-12.
Time frame: Baseline, Months 2, Month 4, and Month 6
Anxiety
Measured by the Patient Reported Outcomes Measurement Information System (PROMIS) anxiety short form using questions on a scale ranging from 1 (never) to 5 (always).
Time frame: Baseline, Month 1, Month 2, Month 4, and Month 6
Changes in patient-reported symptoms: fatigue
Measured by PROMIS FACIT-Fatigue to assess how tired, weak, or limited a person feels due to fatigue. Will use the 13-item measure for symptoms in the past 7 days using questions on a scale ranging from 1 (not at all) to 5 (very much).
Time frame: Baseline, Month 1, Month 2, Month 4, and Month 6
Changes in patient-reported symptoms: mental health
Measured by PROMIS to assess symptoms of mental health such as sadness, worthlessness, and hopelessness. Will use the 8-item measures for symptoms in the past 7 days using questions on a scale ranging from 1 (never) to 5 (always).
Time frame: Baseline, Month 1, Month 2, Month 4, and Month 6]
Changes in patient-reported symptoms: global health
Measured by PROMIS to assess symptoms of global health (QoL). Global health is assessed with a 10-item measure that asks about physical, mental and social functioning using questions on a scale ranging from 1 (poor/not at all/always/sever) to 5 (excellent/completely/never/none) and a 0 (no pain) to 10 (worst imaginable pain) scale.
Time frame: Baseline, Month 1, Month 2, Month 4, and Month 6
Sexual function and satisfaction
Assessed with a 14-item measure in the past 30 days and is specific to either male or female
Time frame: Baseline, Month 1, Month 2, Month 4, and Month 6
Sleep Behavior: total sleep time
Measured using ActiGraph Link, we will have extended wear time to measures total sleep time over a 3-day monitoring period.
Time frame: Baseline, Months 2, Month 4, and Month 6
Inflammation - high sensitivity C-Reactive Protein (hsCRP)
Measured using a self-administered dried blood spot (DBS) collection kit. Participants are taught by research staff and follow a YouTube video to use a finger stick poke to obtain a drop of blood that is put onto a sample card. DBS captured on the designated card are dried thoroughly (\> 4 hours at room temperature), then inserted into a foil pouch with desiccant and mailed to the research team. Cards are frozen (0 degree Fahrenheit \[F\] or below) until analyzed.
Time frame: Baseline, Months 2, and Month 6
Plan to share: Yes — All individual quantitative participant data collected during the trial, after deidentification.
Time frame: Beginning 3 months following final publication.
Access criteria: Access will be provided to investigators who provide a methodologically sound proposal and complete a data sharing agreement that includes commitments to: (1) using the data only for research purposes and not to identify any individual participant, (2) securing the data using appropriate computer technology, and (3) destroying or returning the data after analyses are completed. Proposals should be directed to wintersk@ohsu.edu. To gain access to data, data requestors will need to sign a data sharing agreement.
No publications or documents are linked to this record.
Started Apr 2024 (actual). Primary completion is estimated for Jun 2028, 50 months after the start.
Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 50 months is below that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
OHSU Knight Cancer Institute →